THE ARISING · Longevity & Healthspan
Model Links Harsher Breast Cancer Chemotherapy to Earlier Aging-Related Disease
A computer model projects earlier aging-related mortality after more cytotoxic breast cancer chemotherapy. Its life-year estimates are simulated outcomes, not losses observed in patients.
The finding comes from a computer simulation, not from tracking patients. Published in JAMA Network Open in 2026, the study used an established breast cancer model from the Cancer Intervention and Surveillance Modeling Network. It simulated 400 million US women diagnosed with breast cancer between ages 30 and 79, with diagnoses between 1990 and 2030 and follow-up until death.
The model tracked biological aging, meaning a body that is older than its birth date suggests. It modeled this using data on p16INK4a, a marker of senescent cells. These are cells that have stopped dividing but resist dying. The model assumed that chemotherapy-driven senescence affected only deaths from causes other than breast cancer.
The researchers ran two scenarios. In one, every woman received an anthracycline. In the other, every woman received a nonanthracycline regimen. Anthracyclines are the more cytotoxic, or cell-damaging, option in this comparison.
The model projected a loss of 9.4 years of remaining life (interquartile range, 7.6 to 11.2). The risk of death from causes other than breast cancer was projected to overtake the risk of death from breast cancer 16 years earlier than expected for their chronological age (interquartile range, 12 to 19).
Comparing the two regimens, women on the more cytotoxic one were estimated to lose a median of 7.6 more years of life (interquartile range, 7.0 to 8.0). The study attributes this to aging-related diseases starting earlier. Results varied widely, and the spread was greater for women diagnosed at younger ages than at older ages.
The study also reported a trade-off. Survival from breast cancer was higher with the more cytotoxic regimens. That benefit came paired with a greater potential risk of earlier death from other causes because of age acceleration. The model closely reproduced all-cause survival and 8-year breast cancer survival seen in the Anthracycline for Early Breast Cancer trials.
For survivors and their doctors, the authors say the value lies in awareness and in survivorship care. They write that integrating knowledge about biological aging into that care could inform future research on accelerated aging among survivors. According to GEN, which covered the study, the researchers said oncologists should not change treatment decisions because of possible accelerated aging, since the goal of treatment is to improve breast cancer survival.
The authors add that as evidence on senolytic and other anti-aging drugs develops, modeling may help identify survivors who could benefit. These potential uses still need clinical testing.
Next to watch is research testing whether measuring and managing biological age improves cancer survivors’ outcomes. The simulation alone does not establish how an individual’s cancer treatment should change.